Report of Four Azole-Resistant Aspergillus fumigatus Isolates with TR34 or TR46 Mutations in Japan Referred to a...

It was already known that azole-resistant Aspergillus fumigatus (ARAf) represents a significant global health challenge due to its impact on clinical outcomes and treatment efficacy. The fungus utilizes 14α-demethylase, an enzyme encoded by the cyp51A gene, as a primary target for antifungal therapy in human patients. Mutations within this specific genetic locus frequently confer resistance to triazole medications, which are the first-line defense against invasive aspergillosis. Historically, Japanese clinical isolates primarily exhibited single point mutations in the Cyp51A protein as the dominant mechanism of resistance. Recent international surveillance data indicate a shift toward more complex resistance mechanisms involving tandem repeats (TRs) in the promoter region of the gene. These tandem repeats, specifically the 34 and 46 base-pair variants, are often associated with environmental exposure to fungicides. This absence of evidence motivated the current investigation into the changing landscape of fungal resistance within domestic clinical settings.

This investigation characterizes the emergence of tandem repeat mutations in Japanese clinical isolates of Aspergillus fumigatus to assess shifting resistance patterns. Researchers sought to determine if the prevalence of TR34 and TR46 variants is increasing within the national population compared to historical point mutation trends. The study evaluates the specific genetic profiles of strains referred to a central mycosis reference institution during the 2024 calendar year. Monitoring these shifts is essential for updating local treatment guidelines and diagnostic protocols for managing fungal infections. The work addresses the potential public health threat posed by these highly resistant fungal strains in the context of Japanese healthcare. By identifying the specific molecular drivers of resistance, the study aims to provide a foundation for future epidemiological surveillance.

The research team analyzed 111 distinct A. fumigatus strains submitted to a specialized mycosis reference center for detailed examination and susceptibility profiling. Scientists performed molecular screening to identify mutations in the cyp51A gene and its associated promoter region using targeted sequencing. The protocol specifically targeted the detection of 34 and 46 base-pair tandem repeats alongside specific amino acid substitutions in the coding region to identify tandem repeat azole-resistant Aspergillus fumigatus (TR-ARAf). Each isolate underwent rigorous susceptibility testing to confirm its azole-resistant status and categorize the underlying molecular mechanism. The investigators compared these 2024 findings against historical data collected from clinical samples received before the current year to identify temporal trends. The methodology ensured that even low-frequency resistance alleles were captured during the genetic screening process.

Analysis revealed that four out of ten azole-resistant isolates contained tandem repeat mutations in the cyp51A promoter region. Among the 111 total strains referred in 2024, approximately 9% were classified as azole-resistant Aspergillus fumigatus based on their phenotypic response. The study identified both TR34 and TR46 variants, which were previously rare in Japanese clinical environments but are now appearing more frequently. These specific genotypes involve tandem repeats of 34 or 46 base-pairs coupled with coding region substitutions that alter the 14α-demethylase enzyme. The data indicate a notable shift from simple point mutations to these more complex resistance mechanisms within the Japanese fungal population. The findings highlight that nearly half of the resistant strains now carry these complex tandem repeat alterations.

The increasing detection of TR34 and TR46 mutations suggests that azole-resistant Aspergillus fumigatus is becoming a more prominent threat in Japan. These findings imply that the management of aspergillosis may require more intensive diagnostic surveillance and updated therapeutic strategies in the near future. The researchers suggest that the domestic prevalence of these resistant strains is potentially on the rise, mirroring trends observed in other global regions. Future clinical practice must account for the possibility of environmental or imported resistance mechanisms when treating fungal infections. This study underscores the necessity for ongoing monitoring at reference centers to safeguard public health against evolving fungal pathogens. Enhanced surveillance programs are recommended to track the spread of these mutations across different Japanese prefectures.